Compare FSM & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSM | LGND |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | Canada | United States |
| Employees | N/A | 68 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2005 | N/A |
| Metric | FSM | LGND |
|---|---|---|
| Price | $9.58 | $234.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $14.00 | ★ $247.29 |
| AVG Volume (30 Days) | ★ 5.9M | 179.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.01 | $1.25 |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | ★ $14.10 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.33 | $98.90 |
| 52 Week High | $13.85 | $247.38 |
| Indicator | FSM | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 60.36 |
| Support Level | $9.33 | $180.85 |
| Resistance Level | $9.95 | N/A |
| Average True Range (ATR) | 0.35 | 10.11 |
| MACD | -0.05 | 1.34 |
| Stochastic Oscillator | 5.93 | 67.93 |
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.